NUVA
$53.53
Nuvasive
($.88)
(1.62%)
NUVA
Earnings Whisper ®
N/A
2nd Quarter June 2020
Consensus:  ($0.52)
Revenue:  $186.40 Mil
Wednesday
Aug 5
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when NUVA reports earnings?
Beat
Meet
Miss

Where is NUVA's stock price going from here?
Up
Flat
Down
Stock chart of NUVA
Analysts
Summary of analysts' recommendations for NUVA
Score
Grade
Pivots
Resistance
$57.61
$56.30
$54.92

$53.61

Support
$52.23
$50.92
$49.54
Tweet
Growth
Description
NUVASIVE is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $4.2 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS, as well as a growing offering of cervical and motion preservation products.
Peers
StrykerBoston ScientificAbbottBecton, DickinsonBaxter InternationalWatersTeleflexIntegra LifeSciences Holdings3MCardiovascular Systems